PD98059

For research use only. Not for use in humans.

目录号：S1177

CAS No. 167869-21-8

PD98059 是一种非ATP竞争性的MEK抑制剂，无细胞试验中IC50为2 μM，特异性抑制MEK-1介导的MAPK激活；不直接抑制ERK1或ERK2。PD98059 是一种aryl hydrocarbon receptor (AHR)的配体并起到拮抗剂的功能。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1099.68	现货
10mg	RMB 1213.08	现货
50mg	RMB 3845.73	现货
200mg	RMB 5489.52	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PD98059发表文献353篇：

Immunity, 2021, S1074-7613(20)30538-0

PubMed: 33421362 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):17-32

PubMed: 30645973 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):329-344

PubMed: 28089908 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):840-855

PubMed: 29232556 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Cancer Cell, 2014, 26(5):754-69

PubMed: 25446900 ( click the link to review the publication )

ACS Omega, 2021, 6(7):4759-4766

PubMed: 33644583 ( click the link to review the publication )

Biochem Pharmacol, 2021, 186:114479

PubMed: 33617842 ( click the link to review the publication )

J Ethnopharmacol, 2021, 270:113783

PubMed: 33421596 ( click the link to review the publication )

J Cell Physiol, 2021, 236(2):1375-1390

PubMed: 33128793 ( click the link to review the publication )

Am J Transl Res, 2021, 13(2):708-718

PubMed: 33594320 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz5913

PubMed: 32494742 ( click the link to review the publication )

Cell Rep, 2020, 7;30(1):215-228 e5

PubMed: 31914388 ( click the link to review the publication )

Part Fibre Toxicol, 2020, 17(1):46

PubMed: 32948194 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2795

PubMed: 33003386 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3216

PubMed: 33142778 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Glia, 2020, 10.1002/glia.23790

PubMed: 32036619 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000186RRR

PubMed: 32918765 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):28

PubMed: 31964421 ( click the link to review the publication )
Oxid Med Cell Longev, 2020, 12;2020:6837982

PubMed: 32318240 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00554-0

PubMed: 32910411 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Cancer Biol Med, 2020, 17(2):357-370

PubMed: 32587774 ( click the link to review the publication )

Chemosphere, 2020, 246:125774

PubMed: 31901531 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Int J Mol Sci, 2020, 16;21(10):E3527

PubMed: 32429376 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(4)

PubMed: 32074942 ( click the link to review the publication )

Microorganisms, 2020, 11;8(3) pii: E389

PubMed: 32168837 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2020, 1;318(5):E613-E624

PubMed: 32154742 ( click the link to review the publication )

J Biol Chem, 2020, 295(3):673-689

PubMed: 31780563 ( click the link to review the publication )

Endocrinology, 2020, 161(12)bqaa190

PubMed: 33068422 ( click the link to review the publication )

Biomed Pharmacother, 2020, 23;128:110245

PubMed: 32454290 ( click the link to review the publication )

Biomed Pharmacother, 2020, 131:110724

PubMed: 32920518 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2020, 10.1152/ajpheart.00606.2020

PubMed: 33337962 ( click the link to review the publication )

Life Sci, 2020, 13;252:117666

PubMed: 32298737 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Food Funct, 2020, 11(12):10968-10978

PubMed: 33283791 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:105979

PubMed: 31771816 ( click the link to review the publication )

Eur J Pharmacol, 2020, 868:172886

PubMed: 31866407 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(1):21-33

PubMed: 31810383 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):171

PubMed: 32560675 ( click the link to review the publication )
Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

Cardiovasc Drugs Ther, 2020, 10.1007/s10557-020-07117-3

PubMed: 33242203 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):492-498

PubMed: 31677783 ( click the link to review the publication )

Onco Targets Ther, 2020, 2;13:2757-2769

PubMed: 32308411 ( click the link to review the publication )

Int J Gen Med, 2020, 13:1495-1507

PubMed: 33328759 ( click the link to review the publication )

Biomed Pharmacother, 2020, 121:109669

PubMed: 31766100 ( click the link to review the publication )

J Ethnopharmacol, 2020, S0378-8741(20)33532-7

PubMed: 33264660 ( click the link to review the publication )

Curr Eye Res, 2020, 10.1080/02713683

PubMed: 31951764 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):1064-1071

PubMed: 32070494 ( click the link to review the publication )

Neuroreport, 2020, 31(14):1007-1014

PubMed: 32815825 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30250-4

PubMed: 33129993 ( click the link to review the publication )

Brain Inj, 2020, 34(9):1277-1282

PubMed: 32749897 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15665

PubMed: 32705806 ( click the link to review the publication )

Bone, 2020, 141:115573

PubMed: 32768686 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Am J Chin Med, 2020, 48(1):223-244

PubMed: 32054305 ( click the link to review the publication )

Oral Dis, 2020, 10.1111

PubMed: 32176411 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:7165-7176

PubMed: 32801748 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3557-3576

PubMed: 32774719 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(8):4480-4493

PubMed: 32168416 ( click the link to review the publication )

Drug Deliv Transl Res, 2020, 7

PubMed: 32378175 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:1128

PubMed: 30850660 ( click the link to review the publication )
EMBO J, 2019, 38(12)

PubMed: 31068361 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-19-1555

PubMed: 31744816 ( click the link to review the publication )

BMC Med, 2019, 17(1):42

PubMed: 30782145 ( click the link to review the publication )

Oncogene, 2019, 38(49):7433-7446

PubMed: 31427736 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Antioxid Redox Signal, 2019, 31(12):804-818

PubMed: 31088299 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Emerg Microbes Infect, 2019, 8(1):934-945

PubMed: 31237474 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E75

PubMed: 30641867 ( click the link to review the publication )

Free Radic Biol Med, 2019, 141:21-33

PubMed: 31167117 ( click the link to review the publication )

J Clin Med, 2019, 8(6)

PubMed: 31238539 ( click the link to review the publication )

FASEB J, 2019,

PubMed: 30458112 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):75

PubMed: 31307477 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(22):10610-10625

PubMed: 31785145 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12575

PubMed: 30838710 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):80

PubMed: 30849996 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):350

PubMed: 31775870 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:4546975

PubMed: 31049135 ( click the link to review the publication )

Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

J Recept Signal Transduct Res, 2019, 39(2):175-186

PubMed: 31354091 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):20779-20789

PubMed: 31025337 ( click the link to review the publication )

J Cell Physiol, 2019, 234(4):4504-4514

PubMed: 30246502 ( click the link to review the publication )
J Cell Physiol, 2019, 234(6):8846-8861

PubMed: 30317597 ( click the link to review the publication )

Front Oncol, 2019, 9:1244

PubMed: 31799197 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Sci Rep, 2019, 9(1):840

PubMed: 30696869 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(8):1685-1695

PubMed: 31360111 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

Int J Biol Macromol, 2019, 135:212-225

PubMed: 31108149 ( click the link to review the publication )

Gene, 2019, 683:195-209

PubMed: 30340049 ( click the link to review the publication )

Inflammopharmacology, 2019, 27(3):561-571

PubMed: 30251233 ( click the link to review the publication )

Mar Drugs, 2019, 17(1)E36

PubMed: 30626153 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:2653-2661

PubMed: 31114328 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Cell Signal, 2019, 54:17-26

PubMed: 30471465 ( click the link to review the publication )

Biomed Pharmacother, 2019, 116:109032

PubMed: 31163381 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):12500-12507

PubMed: 30834595 ( click the link to review the publication )

Life Sci, 2019, 229:1-12

PubMed: 30910647 ( click the link to review the publication )

Phytother Res, 2019, 33(8):2102-2117

PubMed: 31209984 ( click the link to review the publication )

Exp Cell Res, 2019, 379(1):65-72

PubMed: 30898547 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

Cell Cycle, 2019, 18(21):2928-2938

PubMed: 31496351 ( click the link to review the publication )

Chem Biol Interact, 2019, 310:108741

PubMed: 31299238 ( click the link to review the publication )
J Cancer Res Clin Oncol, 2019, 145(2):411-427

PubMed: 30483898 ( click the link to review the publication )

Am J Transl Res, 2019, 11(9):5824-5835

PubMed: 31632551 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(11):2344-2353

PubMed: 31498445 ( click the link to review the publication )

Int Immunopharmacol, 2019, 77:105955

PubMed: 31678866 ( click the link to review the publication )

Toxicol In Vitro, 2019, 56:156-162

PubMed: 30677511 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30901941 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3292-3304

PubMed: 31002345 ( click the link to review the publication )

Free Radic Res, 2019, 53(3):348-358

PubMed: 30773942 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2019, 10.1016/j

PubMed: 31422034 ( click the link to review the publication )

Environ Toxicol, 2019, 34(6):679-688

PubMed: 30801954 ( click the link to review the publication )

Am J Reprod Immunol, 2019, 81(1):e13073

PubMed: 30461130 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.110

PubMed: 31761326 ( click the link to review the publication )

Lipids Health Dis, 2019, 18(1):71

PubMed: 30909920 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3851718

PubMed: 30993112 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2019, 51(10):1056-1063

PubMed: 31555794 ( click the link to review the publication )

Med Sci Monit, 2019, 25:6491-6503

PubMed: 31465316 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7666-7674

PubMed: 31605603 ( click the link to review the publication )

Cell Biochem Biophys, 2019, 77(4):367-377

PubMed: 31659617 ( click the link to review the publication )

Cell Reprogram, 2019, 21(5):238-248

PubMed: 31369321 ( click the link to review the publication )

Life Sci, 2019, 235:116863

PubMed: 31513817 ( click the link to review the publication )

Biosci Rep, 2019, 39(11)

PubMed: 31548362 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)E840

PubMed: 31216681 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )
Commun Biol, 2019, 2:359

PubMed: 31602408 ( click the link to review the publication )

Biochim Biophys Acta Gene Regul Mech, 2019, 1862(8):846-857

PubMed: 31054961 ( click the link to review the publication )

Am J Chin Med, 2019, 913-931

PubMed: 31096773 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(5):617-627

PubMed: 30817168 ( click the link to review the publication )

Nutrients, 2019, 11(4)E782

PubMed: 30987344 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Oncogene, 2018,

PubMed: 29059160 ( click the link to review the publication )

Oncogene, 2018, 37(24):3275-3289

PubMed: 29551771 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):113

PubMed: 29866133 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 17;37(1):8

PubMed: 29343273 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1140

PubMed: 30442927 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Br J Cancer, 2018, 119(9):1094-1105

PubMed: 30401978 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Hum Reprod, 2018, 33(11):2096-2106

PubMed: 30272163 ( click the link to review the publication )

J Cancer, 2018, 9(23):4449-4462

PubMed: 30519351 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(2):177-190

PubMed: 29217477 ( click the link to review the publication )

Oxid Med Cell Longev, 2018, 2018:4572893

PubMed: 30538801 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(1):57-66

PubMed: 28964848 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(7):3340-3352

PubMed: 29566307 ( click the link to review the publication )

Sci Rep, 2018, 8(1-:10070

PubMed: 29968778 ( click the link to review the publication )
Sci Rep, 2018, 8(1):3120

PubMed: 29449636 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Inflammopharmacology, 2018, 10.1007/s10787-018-0492-y

PubMed: 29748880 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:320-325

PubMed: 29864620 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:282-289

PubMed: 29860220 ( click the link to review the publication )

Tissue Eng Part A, 2018, 24(5-6):502-515

PubMed: 28602124 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):300-313

PubMed: 28569433 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(41):10721-10728

PubMed: 30257559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(2):109-117

PubMed: 25588050 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Cancer Med, 2018,

PubMed: 29239135 ( click the link to review the publication )

Biochimie, 2018, 152:43-52

PubMed: 29960031 ( click the link to review the publication )

Molecules, 2018,

PubMed: 30513793 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Neurochem Res, 2018, 43(10-:1963-1977

PubMed: 30136162 ( click the link to review the publication )

PLoS One, 2018, 13(9):e0203402

PubMed: 30192802 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0197422

PubMed: 29763460 ( click the link to review the publication )

PLoS One, 2018, 13(7):e0200878

PubMed: 30048489 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(4):1291-1295

PubMed: 29412164 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(3):155-165

PubMed: 29441602 ( click the link to review the publication )
Cell Biol Int, 2018, 42(5):598-607

PubMed: 29345412 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):7443-7449

PubMed: 29731895 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8442-8446

PubMed: 29805580 ( click the link to review the publication )

In Vivo, 2018, 32(3):549-554

PubMed: 29695559 ( click the link to review the publication )

In Vivo, 2018, 32(6):1361-1368

PubMed: 30348689 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):115

PubMed: 29866191 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(31):8307-8318

PubMed: 29961319 ( click the link to review the publication )

Sci Total Environ, 2018, 643:496-506

PubMed: 29945085 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Dev Cell, 2017, 41(5):527-539.e5

PubMed: 28586645 ( click the link to review the publication )

Oncogene, 2017, 36(46):6359-6373

PubMed: 28745319 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(2):73-92

PubMed: 27650197 ( click the link to review the publication )

Cancer Lett, 2017, 395:31-44

PubMed: 28268166 ( click the link to review the publication )

Cancer Lett, 2017, 401:1-10

PubMed: 28483515 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006321

PubMed: 28394926 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 41(5):1957-1969

PubMed: 28391263 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(9):1694-1704

PubMed: 28674151 ( click the link to review the publication )

J Neurochem, 2017, 142(2):231-245

PubMed: 28444734 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13319

PubMed: 29042627 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 171:318-327

PubMed: 28529129 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3281-3291

PubMed: 28651331 ( click the link to review the publication )

Immunol Cell Biol, 2017, 95(10):943-952

PubMed: 28878297 ( click the link to review the publication )
Biomed Pharmacother, 2017, 89:1037-1044

PubMed: 28292012 ( click the link to review the publication )

Biomed Pharmacother, 2017, 87:332-341

PubMed: 28064106 ( click the link to review the publication )

Brain Res Bull, 2017, 130:236-244

PubMed: 28189515 ( click the link to review the publication )

Exp Cell Res, 2017, 360(2):281-291

PubMed: 28919123 ( click the link to review the publication )

Chem Biol Interact, 2017, 270:1-8

PubMed: 28390675 ( click the link to review the publication )

Am J Transl Res, 2017, 9(6):2878-2890

PubMed: 28670376 ( click the link to review the publication )

Dev Comp Immunol, 2017, 76:392-402

PubMed: 28713009 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1036-1044

PubMed: 28000898 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Neurochem Res, 2017, 10.1007/s11064-017-2174-3

PubMed: 28083849 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189920

PubMed: 29261770 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:627-643

PubMed: 28223821 ( click the link to review the publication )

DNA Cell Biol, 2017, 36(11):1029-1038

PubMed: 28945461 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 492(2):206-211

PubMed: 28821432 ( click the link to review the publication )

Food Nutr Res, 2017, 61(1):1368321

PubMed: 28970779 ( click the link to review the publication )

Microb Pathog, 2017, 10.1016/j.micpath

PubMed: 28131949 ( click the link to review the publication )

Cell Biochem Funct, 2017, 35(5):278-286

PubMed: 28749079 ( click the link to review the publication )

Cell Biol Int, 2017, 41(12):1307-1315

PubMed: 28816402 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:5985703

PubMed: 28167972 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1445-1450

PubMed: 29067463 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1417-1424

PubMed: 28627644 ( click the link to review the publication )

Poult Sci, 2017, 96(9):3043-3051

PubMed: 28431078 ( click the link to review the publication )
Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Drug Discov Ther, 2017, 11(4):212-217

PubMed: 28867754 ( click the link to review the publication )

Cell Prolif, 2017, 50(1)

PubMed: 27790820 ( click the link to review the publication )

Anesthesiology, 2017, 126(5):868-881

PubMed: 28121635 ( click the link to review the publication )

Oncotarget, 2017, 8(15):24237-24249

PubMed: 27458161 ( click the link to review the publication )

Menopause, 2017, 24(4):437-451

PubMed: 27922937 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55084-55093

PubMed: 28903404 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(4):524-34

PubMed: 26166769 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):640-50

PubMed: 27593484 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2435

PubMed: 27787522 ( click the link to review the publication )

Stem Cells, 2016, 34(11):2744-2757

PubMed: 27340942 ( click the link to review the publication )

Mol Oncol, 2016, 10(6):775-88

PubMed: 26842883 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:2572175

PubMed: 26962394 ( click the link to review the publication )

J Transl Med, 2016, 14:46

PubMed: 26861698 ( click the link to review the publication )

J Ethnopharmacol, 2016, 193:293-302

PubMed: 27553977 ( click the link to review the publication )

Prostate, 2016, 76(3):273-85

PubMed: 26499308 ( click the link to review the publication )

Exp Cell Res, 2016, 345(1):82-92

PubMed: 27237094 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 80:132-142

PubMed: 27702651 ( click the link to review the publication )

Cell Immunol, 2016, 310:63-70

PubMed: 27687530 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )
Neurochem Res, 2016, 41(7):1635-44

PubMed: 26961889 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146554

PubMed: 26752289 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(2):330-7

PubMed: 27107695 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Pharm Biol, 2016, 54(10):2220-35

PubMed: 27049854 ( click the link to review the publication )

Exp Ther Med, 2016, 11(6):2413-2419

PubMed: 27284329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27874-88

PubMed: 27036049 ( click the link to review the publication )

Sci Rep, 2016, 6:30121

PubMed: 27444207 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43442-43460

PubMed: 27259276 ( click the link to review the publication )

Toxicol Res (Camb), 2016, 5(6):1573-1584

PubMed: 30090458 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10257-67

PubMed: 26831668 ( click the link to review the publication )

Tumour Biol, 2016, 37(3):3727-38

PubMed: 26468015 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48501-48516

PubMed: 27384485 ( click the link to review the publication )

Pflugers Arch, 2016, 468(11-12):2041-2051

PubMed: 27592222 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22623-31

PubMed: 26980707 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27322144 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms9390

PubMed: 26399630 ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(12):2471-9

PubMed: 26331632 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2660-72

PubMed: 26609474 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

J Transl Med, 2015, 13(1):42

PubMed: 25638174 ( click the link to review the publication )

Sci Rep, 2015, 5:18314

PubMed: 26658818 ( click the link to review the publication )
J Nat Prod, 2015, 78(7):1689-96

PubMed: 26171689 ( click the link to review the publication )

Cytokine, 2015, 17:139-144

PubMed: ( click the link to review the publication )

Cytokine, 2015, 71(2):139-44

PubMed: 25461391 ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22830

PubMed: 25731708 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 585:10-16

PubMed: 26363213 ( click the link to review the publication )

Toxicol In Vitro, 2015, 30(1 Pt B):521-8

PubMed: 26363202 ( click the link to review the publication )

Neurochem Res, 2015, 40(8):1609-19

PubMed: 26088686 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122109

PubMed: 25853521 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

Exp Biol Med, 2015, 10.1177/1535370215576312

PubMed: 25767191 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Acta Biochim Biophys Sin, 2015, 47(7), 1–9

PubMed: 26071572 ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(3):134-42

PubMed: 25753185 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2015, 2015:307594

PubMed: 25802536 ( click the link to review the publication )

Tissue Cell, 2015, 47(3):301-10

PubMed: 25958163 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Genet Mol Res, 2015, 14(4):18325-33

PubMed: 26782480 ( click the link to review the publication )

EMBO Mol Med, 2014, 6(6):821-34

PubMed: 24778454 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1428

PubMed: 25275589 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1187

PubMed: 24743742 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )
Thromb Haemost, 2014, 112(5):992-1001

PubMed: 25057055 ( click the link to review the publication )

Cell Microbiol, 2014, 16(9):1441-55

PubMed: 24779413 ( click the link to review the publication )

Biomed Pharmacother, 2014, 68(8):1037-43

PubMed: 25312822 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Toxicol Lett, 2014, 226(1):81-9

PubMed: 24495410 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2777-88

PubMed: 25335112 ( click the link to review the publication )

J Periodontal Res, 2014, 10.1111/jre.12193

PubMed: 24854880 ( click the link to review the publication )

PLoS One, 2014, 9(3):e85705

PubMed: 24633332 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87311

PubMed: 24489893 ( click the link to review the publication )

PLoS One, 2014, 9(5):e94753

PubMed: 24787138 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):167-72

PubMed: 24582558 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 64(2):180-90

PubMed: 24705173 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2014, Zhang JL

PubMed: ( click the link to review the publication )

Oncol Lett, 2014, 8(4):1739-1744

PubMed: 25202402 ( click the link to review the publication )

Regul Pept, 2014, 194-195:41-8

PubMed: 25450576 ( click the link to review the publication )

Hepatology, 2013, 59(4):1262-72

PubMed: 23929627 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

J Thromb Haemost, 2013, 12(3):395-408

PubMed: 24354620 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2013, 144PA:223-227

PubMed: 24514755 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 375(1-2):89-96

PubMed: 23707617 ( click the link to review the publication )

Cell Signal, 2013, 26(3):512-20

PubMed: 24308969 ( click the link to review the publication )
Microbes Infect, 2013, 15(2):105-14

PubMed: 23164610 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82610

PubMed: 24340049 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70732

PubMed: 23967093 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

PLoS One, 2013, 8(12):e85032

PubMed: 24376862 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63890

PubMed: 23667687 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Microbiol Immunol, 2012, 56(11):782-8

PubMed: 22938101 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Atheroscler, 2011, 218(2):486-92

PubMed: 21782178 ( click the link to review the publication )

Int J Mol Med, 2011, 28(1):115-9

PubMed: 21455558 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述

特性

PD98059不会抑制已经被c-Raf磷酸化的 MEK1

靶点

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

体外研究

PD98059 要么抑制本底的MEK1，要么抑制一种被部分激活的MEK突变体，该突变体是 218 和 222号位上丝氨酸突变为谷氨酸后形成的(MEK-2E)， IC50 为2 μM. PD98059 不会抑制JNK和P38这两个 MAPK 的同系物. PD98059会高度选择性的抑制MEK, 因为对其它包括Raf 激酶, cAMP-依赖性激酶, 蛋白激酶C, v-Src, 表皮生长因子 (EGF) 受体激酶, 胰岛素受体激酶, PDGF 受体激酶, 和磷脂酰肌醇(-3)激酶等在内的一系列激酶都没有抑制性。 PD98059 会抑制经过PDGF刺激而活化的MAPK 和胸苷进入 3T3 细胞， IC50分别为 ~10 μM 和 ~7 μM ^[1]。PD98059可以有效地阻止 MEK1 被Raf 或者MEK 激酶活化， IC50为4 μM, 可以微弱地抑制MEK2被 Raf 活化， IC50 为50 μM。在KB 和 PC12 细胞中, PD98059 不会抑制MKK4 和RK激酶这两个参与压力和白细胞介素-1介导的激酶级联反应的MEK的同系物的活化，在Swiss 3T3 细胞中也不会通过胰岛素或者表皮生长因子抑制p70 S6 激酶的活化^[2]。PD98059会在不改变细胞生存能力的情况下完全阻断神经生长因子(NGF)诱导的 PC12 细胞的分化^[3] 。PD98059会以剂量依赖性的方式抑制培养在含有破骨细胞分化因子培养基中的 RAW264.7细胞的增值，进而导致TRAP阳性细胞数量明显下降^[6]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A2780	NWDrRYhLTnWwY4Tpc44hSXO\|YYm=	M4DPfFIxyqEQvF2=	MnLuNUBp		NUPCPJh{[myxY3vzJGRVS0RvaX7keYNm\CCGUkWg[ZhxemW\|c3nvci=>	M4XTOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nkm2PFYzLz5{M{[5Olg3OjxxYU6=
AML 1#	M3O5WmFxd3C2b4Ppd{BCe3OjeR?=	NHXVNJczOMLizszN	Mn7kNVIhcA>?		MYPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx	M4\lelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C2OlkyLz5{M{ewOlY6OTxxYU6=
KG-1	NFnrd49CeG:ydH;zbZMhSXO\|YYm=	NYTj[JZuOjEEoN88US=>	NVvabpJVOTJiaB?=		Mn\X[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=>	MoHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[2PVEoRjJ\|N{C2OlkyRC:jPh?=
HUVECs	NY\JUWZmSXCxcITvd4l{KEG\|c3H5	MUeyM\|Qh\|ryP	NGjBe2EzPC92ODDo		NYHme25lcW6mdXPld{Bk\WyuIHTlZZRp	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{WyNEc,OjN5MEe1NlA9N2F-
HepG2	NWSxWo01TnWwY4Tpc44hSXO\|YYm=	NWDvPVBDOjEEoN88US=>	NFTDU4EzPCCq		M333RYlvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW\|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu	NGq0PWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|YxQSd-MkO3NFc3ODl:L3G+
NB4	NVe1SmZFSXCxcITvd4l{KEG\|c3H5	Mo\6NVAwOjBxNkCg{txO	NV7ucFhROS53IHi=	NI[ydWFFVVOR	M4PEVIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdHXkJJdqfGhiUHHjcIl1[XinbB?=	NYLvbohCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|U2PDFpPkKzO\|M2PTRzPD;hQi=>
BxPC-3 cells	NF;4dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKyNOKh\|ryP	MXuwMlUhcA>?		NHGwXVFqdmirYnn0d{BXTUeILVGtdoVofWyjdHXkJGhWXkWFIHfyc5d1cCCjbnSgeJVj\SCob4LtZZRqd25iaX7keYNm\CCkeTDQRXIuOiCDUB?=	NF\sVYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e2OFA1Pid-MkO3OlQxPDZ:L3G+
MKN45	NI\V[ZNCeG:ydH;zbZMhSXO\|YYm=	M3\BZVExKM7:TdMg	NFrrelAzPCCq		MYjpcoNz\WG\|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
SGC7901	MVrBdI9xfG:\|aYOgRZN{[Xl?	M3G5[VExKM7:TdMg	NWiwWmtvOjRiaB?=		M4ezdYlv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m\|	Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
MKN45	Ml\pSpVv[3Srb36gRZN{[Xl?	NFLBb4wyOCEQvF5CpC=>	NY\YOZViOjRiaB?=		M4f2[olvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	MlXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
SGC7901	NUjXN5lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKxNEDPxE4EoB?=	MmO3NlQwPDhxN{KgbC=>		NF7rUFRqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?=	NH\jUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
MKN45	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\SNVAh\|ryPwrC=	Mm[2NlQwPDhxN{KgbC=>		M{fNZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW	M3[3dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOVg5Lz5{M{e5NlU5QDxxYU6=
SGC7901	M2TzR2Z2dmO2aX;uJGF{e2G7	NIC4UIoyOCEQvF5CpC=>	MmjDNlQhcA>?		M{jiUYlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
HUASMCs	MofoSpVv[3Srb36gRZN{[Xl?	MnPONVAh\|ryPwrC=	MlTLNlQhcA>?		MWfkbY1qdmm\|aHXzJGFv\yCLST3jZZV{\WRiU1;DV\|MhdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vyqB?	Mlj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MU[0OlgoRjJ\|OEG2OFY5RC:jPh?=
HUASMCs	MVLGeY5kfGmxbjDBd5NigQ>?	M{jLXFExKM7:TdMg	M1:0dlI1KGh?		NFfNbJBqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXs	M1vsZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEG2OFY5Lz5{M{ixOlQ3QDxxYU6=
EPOR/CR3	MnzKSpVv[3Srb36gRZN{[Xl?	MlTOOVDDqM7:TR?=	M1PtN\|MhcA>?		NGDqR3pz\WS3Y3XzJGVRVyCjbnSvc5IhUUxvMz3pcoR2[2WmIITo[UB1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb39CpC=>	NHHCS249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyNFc{OSd-MkO4NlA4OzF:L3G+
NB4	MWPGeY5kfGmxbjDBd5NigQ>?	NGqzbm8yOCEQvF5CpC=>	NXvpXVh7PzJiaB?=	MlnySG1UVw>?	MoTubY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?=	Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MkW1PFUoRjJ\|OEK1OVg2RC:jPh?=
HL60	NXHjb\|RNTnWwY4Tpc44hSXO\|YYm=	M4Ox[VIxyqEQvF2=	MmDCO\|IhcA>?	MXfEUXNQ	MVPpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{NUW4OUc,OjN6MkW1PFU9N2F-
HUVECs	MoK5SpVv[3Srb36gRZN{[Xl?	MUGyOUDPxE1?	NHzhZnAyKGh?		NVzw[IdCcW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36=	MlTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEGwNFgoRjJ\|OUCxNFA5RC:jPh?=
LNCaP	NF7FWohHfW6ldHnvckBCe3OjeR?=	MWOxNEDPxE4EoB?=	MmPVNUBp		MXXk[YNz\WG\|ZYOgeIhmKEWJRjD1dJJm\3WuYYTl[EBxNVmELUG=	Mn;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{izNVgoRjJ\|OEO4N\|E5RC:jPh?=
HL-60	MojVRZBweHSxc3nzJGF{e2G7	M2rDSVUxyqEQvF2=	MVKxJIg>		M13CfZJme2O3ZYOgRmEyPDVibXXkbYF1\WRiYYDvdJRwe2m\|	Mkj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NEi3OVEoRjJ\|OUS4O\|UyRC:jPh?=
HepG2	NV\yNG81TnWwY4Tpc44hSXO\|YYm=	MUm0NEDPxE1?	NWXTOmY2Pi9zMjDo		MkL2bY5pcWKrdIOgeIhmKGmwY4LlZZNmKG:oIICtSXJMOSCjbnSgdE1kNUq3bjDwdo91\WmwIHX4dJJme3Orb36gZpkhWEx?	NVrGfGZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFI5PTFpPkKzPVQzQDVzPD;hQi=>
HPAF-II	NY\Qc2JzTnWwY4Tpc44hSXO\|YYm=	M133b\|ExKM7:TdMg	NXntb3YxPiCq		NWDLcHV5cW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5M{exNEc,OjN7N{O3NVA9N2F-
BxPC-3	MnzkSpVv[3Srb36gRZN{[Xl?	NYPV[3FIOTBizszNxsA>	MlywOkBp		MYnpcoNz\WG\|ZTDtbXIuOTR\|IHX4dJJme3Orb36=	M4S0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUezO\|ExLz5{M{m3N\|cyODxxYU6=
COLO205	NX7Ke5FJSXCxcITvd4l{KEG\|c3H5	NG\zOpcyOC9{MD:0NEDPxE1?	NHLnR5UzPCCq		NWOyR5N4cW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>?	M164OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG5NVA5Lz5{NECxPVExQDxxYU6=
G292	M13aZ2Fxd3C2b4Ppd{BCe3OjeR?=	MoXKN\|DDqM7:TR?=	Mo\KNkBp		M2[0WZJme3SxcnXzJINieHOjaXPpck1qdmS3Y3XkJINmdGxiZHXheIg>	M3TBS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEGyPVMxLz5{NECxNlk{ODxxYU6=
SGC7901	MWHBdI9xfG:\|aYOgRZN{[Xl?	MVOyNOKh\|ryP	MXqxJIg>		MljzbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU	NYTpUnRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNlc4PTBpPkK0NFI4PzVyPD;hQi=>
MGC803	MXTBdI9xfG:\|aYOgRZN{[Xl?	NXn2Xmp{OjEEoN88US=>	M1:3WFEhcA>?		MVHpcohq[mm2czDhdI9xfG:\|aYOgbY5lfWOnZDDifUBKTk5vzsJCpIFv\CB34pEyMWRHXVJ?	NIP6Rog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECyO\|c2OCd-MkSwNlc4PTB:L3G+
HPMC	M2LtVWFxd3C2b4Ppd{BCe3OjeR?=	MXKxNOKh\|ryP	MlG2NlTDqGh?		NVP6V2VTemW4ZYLz[ZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKR2DEVy=>	M4nCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
HCT-8	NFvYPGNCeG:ydH;zbZMhSXO\|YYm=	M4[4fVExyqEQvF2=	NUPTZ3VDOjUEoHi=		NWOxe3dN\GWlcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhPS2IVR?=	NYriUGM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU5PjNpPkK0NFk2QDZ\|PD;hQi=>
HPMC	M1rOTmZ2dmO2aX;uJGF{e2G7	NH33OlAyOMLizszN	NGrFb4k1QCCq		MmjtdoV3\XK\|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM>	M1zmVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
A549	MYjGeY5kfGmxbjDBd5NigQ>?	MkfCOVDDqM7:TR?=	NF;LcngzKGh?		MXXicI9kc3NiRWLLJJBpd3OyaH;yfYxifGmxbjDt[YRq[XSnZDDifUAyNDJvTmG=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4N{eyO{c,OjRyNke3Nlc9N2F-
Caco-2	MnPXRZBweHSxc3nzJGF{e2G7	MXmxNOKh\|ryP	Ml7qNlTDqGh?		M{fLbIRm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV?	NF3mZYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVg3Oyd-MkSwPVU5PjN:L3G+
AGS	NWHxfZVNTnWwY4Tpc44hSXO\|YYm=	MUSxNEDPxE4EoB?=	M3\ZNlAvPSCq		MlnTbY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n	M3S3fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUC2NVY3Lz5{NEGwOlE3PjxxYU6=
Ca9-22	NF;zVoZHfW6ldHnvckBCe3OjeR?=	MmLYN{DPxE1?	MU[xM\|IhcA>?		MX3y[YR2[2W\|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>?	NVXU[3poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlY2OzJpPkK0NVI3PTN{PD;hQi=>
Ca9-22	M{\4dWZ2dmO2aX;uJGF{e2G7	M3[x[\|Mh\|ryP	NFLKOokyKGh?		NIr6NpBi[m:uaYPo[ZMhfGinIHHibYxqfHlib3[gTIJTKHSxIHnu[JVk\SCLTD24JJBzd2S3Y4Tpc44>	MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMk[1N\|IoRjJ2MUK2OVMzRC:jPh?=
HAECs	M{DWOmZ2dmO2aX;uJGF{e2G7	MYKxNEDPxE1?	MXSxJIg>		MmXzxsBifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKEmFQV2tNUBidmRiVlPBUU0yKGW6cILld5Nqd25?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NE[1O{c,OjRzM{S2OVc9N2F-
Caco-2	NYrpVm1yTnWwY4Tpc44hSXO\|YYm=	M1v1TlUxyqEQvF2=	NH;Je3Y1QGh?	NHH0Z5hFVVOR	MoXH[Y5p[W6lZYOgeIhmKG2UTlGgcIV3\Wy\|IH;mxsBUS06QMVGsSnh[TDNuwrDMR3QtyqCOT2isxsBJUUZ\|QT\|CpHpIOTZuwrDQSGU3ScLiYX7kxsBNT0GOU{G2xsBo\W6nc9MgZ48ufHKnYYTl[EB4cXSqIFTlfC=>	M4Xi[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[xOlk2Lz5{NEG2NVY6PTxxYU6=
MCF-7	MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixNEDPxE1?	NXTIfVBXPDiq	NY[zNldjTE2VTx?=	NF7oXnhz\X[ncoPld{BDVkZvaX7keYNm\CClZXzsJIN6[2ynIHHydoV{fA>?	NHPvZYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2N\|QxPCd-MkSxOlM1ODR:L3G+
SMMC7721	NIj2[GxHfW6ldHnvckBCe3OjeR?=	M2XxblI2NzVyIN88US=>	MWqyOEBp		MYTzeZBxemW\|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA>	MnfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNkiwOVYoRjJ2MU[4NFU3RC:jPh?=
SGC7901	Mnm1RZBweHSxc3nzJGF{e2G7	NETz[GM2OMLizszN	M4XyblI1NzR6L{eyJIg>	MUnEUXNQ	NFzre2NqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT\|Ihe2iUTlG=	NFnqcXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3PFI1OCd-MkSxO\|gzPDB:L3G+
7721	MoP2RZBweHSxc3nzJGF{e2G7	MUezNEDPxE1?	NUG2WY1QPSCm		MVLk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	NFTCbJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVI2Oyd-MkSyNVEzPTN:L3G+
DLD-1	NFfIb3FHfW6ldHnvckBCe3OjeR?=	M1v6XFIxyqEQvF2=	M2LNO\|Q5KGh?		NYHhUZh[emWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJzMUW4NUc,OjR{MUG1PFE9N2F-
HT-29	M2nndWZ2dmO2aX;uJGF{e2G7	M3vsPFIxyqEQvF2=	NULpVI1IPDhiaB?=		M3PiZ5Jm\HWlZYOgeIhmKEKQSWCzJIV5eHKnc4Ppc44heHKnLYTy[YF1\WRid3n0bEA2NWG8YT3kRy=>	NISzeYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVU5OSd-MkSyNVE2QDF:L3G+
7402	MnzIRZBweHSxc3nzJGF{e2G7	NFrHT4g{OCEQvF2=	M333RlUh\A>?		M4KzVoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44>	M1vUSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxNlU{Lz5{NEKxNVI2OzxxYU6=
MCF-7	MVLGeY5kfGmxbjDBd5NigQ>?	MVqyNEDPxE1?	M1Tac\|EhcA>?		MVjhZo9tcXOqZYOg[ZhxemW\|c3nvckBw\iCyaH;zdIhwenmuYYTl[EBGWktiY3:teJJm[XSvZX70JJdqfGhiY3;ubpVo[XSn	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJzNkK4PUc,OjR{MU[yPFk9N2F-
MCF-7	NX2xNmRmSXCxcITvd4l{KEG\|c3H5	MX6yNEDPxE1?	NU\4ZoxjOSCq		Mn32bY5kemWjc3XzJINie3Cjc3WtPUBmdnq7bXWgZYN1cX[rdIm=	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MU[yPFkoRjJ2MkG2Nlg6RC:jPh?=
CRL-2302	MorTSpVv[3Srb36gRZN{[Xl?	MX:yNEDPxE1?	MkHWNE42KGh?		NVnPbpY6cW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1	NEfCb3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyO\|kyQCd-MkSyNlc6OTh:L3G+
ARPE-19	NV\DN\|M2TnWwY4Tpc44hSXO\|YYm=	MYmyNEDPxE1?	NVj2bWh{OC53IHi=		MlfwbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ{N{mxPEc,OjR{Mke5NVg9N2F-
MG-63	MVXGeY5kfGmxbjDBd5NigQ>?	MkC1NlAh\|ryP	NX\PVoo5OC53IHi=		Mo\CZoxw[2u\|IITo[UBEUC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJGVNUzFicILveIVqdiCneIDy[ZN{cW:w	NVPVOWRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyN\|k3PDBpPkK0NlM6PjRyPD;hQi=>
SGC-7901	NVXhVlFVSXCxcITvd4l{KEG\|c3H5	M4jjTVIxKM7:TR?=	NYLreWxEOjRiaB?=		NF:wVJpqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN?	NIrTPXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0NVM2OSd-MkSyOFE{PTF:L3G+
NUGC2	NX[0OVF6TnWwY4Tpc44hSXO\|YYm=	NHrsbmk2OCEQvF2=	MXS0PEBp	MlTQSG1UVw>?	NWTVelRtcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NHTzbYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
NUGC3	NI[0[mJHfW6ldHnvckBCe3OjeR?=	MUC1NEDPxE1?	MmLQOFghcA>?	M1PGXmROW09?	NU\UNnhTcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NX\IPXU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KATOIII	M{DwcmZ2dmO2aX;uJGF{e2G7	MUO1NEDPxE1?	NF:zTZI1QCCq	MXLEUXNQ	MnLvbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
NCI-N87	M3jpTmZ2dmO2aX;uJGF{e2G7	MmLPOVAh\|ryP	MWS0PEBp	M3fzUmROW09?	MmXVbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	M2Dtc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
OE19	M1jld2Z2dmO2aX;uJGF{e2G7	MoLoOVAh\|ryP	NGLSSG01QCCq	MWDEUXNQ	NVm1[mNLcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NFrkclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
MKN7	MWHGeY5kfGmxbjDBd5NigQ>?	MmnIOVAh\|ryP	NIqwXJU1QCCq	MlvxSG1UVw>?	NFrQPW9qdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NWHLO5ppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE4	MnTuSpVv[3Srb36gRZN{[Xl?	NG\LXYE2OCEQvF2=	NUC1S3VuPDhiaB?=	M1\3eWROW09?	M1;6SpVxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEiOQTDjcIF{eyCL	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
KYSE30	M4fT[2Z2dmO2aX;uJGF{e2G7	MlPBOVAh\|ryP	MkW2OFghcA>?	MVrEUXNQ	M{PzNpVxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEiOQTDjcIF{eyCL	NFuw[4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
TE5	M3nERWZ2dmO2aX;uJGF{e2G7	NFzNV4Y2OCEQvF2=	NHjieVI1QCCq	NILNfmZFVVOR	MWL1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	NX:3WZpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE1	MnjPSpVv[3Srb36gRZN{[Xl?	Mn7uOVAh\|ryP	MlHUOFghcA>?	NVXBXnAxTE2VTx?=	NFjmd3Z2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	MnfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE3	NH:3cI1HfW6ldHnvckBCe3OjeR?=	M3HjdFUxKM7:TR?=	MonoOFghcA>?	M1i0Z2ROW09?	Mm\KeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	NHjQVJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
KYSE30	NF7kd2RHfW6ldHnvckBCe3OjeR?=	MlP6NlAwPTBxMUCwJO69VQ>?	MWC0PEBp	M{LQ[GROW09?	NIDr[ZpqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
TE1	M{T2fmZ2dmO2aX;uJGF{e2G7	M1TpXFIxNzVyL{GwNEDPxE1?	NYXEXmppPDhiaB?=	MUXEUXNQ	M2XkUolvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M3f4e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE4	MYjGeY5kfGmxbjDBd5NigQ>?	NUTXZ29NOjBxNUCvNVAxKM7:TR?=	M4rIPFQ5KGh?	MnjOSG1UVw>?	MlHpbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MmX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
HT29	MUPGeY5kfGmxbjDBd5NigQ>?	MVSxNEDPxE1?	NEmxcmszKGh?		MnfDbY5pcWKrdIOgc4YhUkGNMjygSXJMOS9{IHHu[EBUXEGWMzDwbI9{eGixconsZZRqd25?	MnLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NkWyPVMoRjJ2Mk[1Nlk{RC:jPh?=
HepG2	MlSzRZBweHSxc3nzJGF{e2G7	NGr5XIEzOCEQvF2=	NV;iXng4OjRiaB?=		MXXpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM>	NVvY[ZJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFc6ODlpPkK0NlQ4QTB7PD;hQi=>
HepG2	NH31OlhHfW6ldHnvckBCe3OjeR?=	M4rLblIxKM7:TR?=	MkK5NkBp		M1\1coVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm=	MoqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEe5NFkoRjJ2MkS3PVA6RC:jPh?=
MC-3	MWTBdI9xfG:\|aYOgRZN{[Xl?	Mn\4NVAh\|ryP	NVvTZVJLOjRiaB?=		NH7Vc5Nxd3SnboTpZZRm\CCPRWPDMYlv\HWlZXSgZZBweHSxc3nzJIlvKCClZXzsdy=>	M1e4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkewOVI{Lz5{NEK3NFUzOzxxYU6=
Raji	MUPGeY5kfGmxbjDBd5NigQ>?	M1HRTFExKM7:TR?=	MUKxJIg>		M3H2fIJtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;u	M{\NelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[5OlMxLz5{NEK2PVY{ODxxYU6=
Raji	NUXUVZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vHXFExKM7:TR?=	NVLJbGF4OSCq		NUHiTnlZcW6qaXLpeJMhfGinIHLhd4FtKG:{IHjzRmFHTi2\|dHnteYxifGWmIHPlcIwheHKxbHnm[ZJifGmxbjDhcoQhfmmjYnnsbZR6	NYWxT2NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3OzBpPkK0NlY6PjNyPD;hQi=>
A549	MoPnSpVv[3Srb36gRZN{[Xl?	MkDaN\|Ah\|ryP	MWKwMlUhcA>?	M2PGcGROW09?	MoXObY5pcWKrdIOgeIhzd22kaX6tbY5lfWOnZDDDM2VDWM7{IGTodlI{PcLicHjvd5Bpd3K7bHH0bY9v	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5N{[5Okc,OjR{N{e2PVY9N2F-
HCSMCs	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfxNVAh\|ryP	NYXxWm1wOjRiaB?=		Mn7wZoxw[2u\|IF\BRnA1NWmwZIXj[YQhUEODU13DJJBzd2yrZnXyZZRqd25?	MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MUKzPFEoRjJ2M{GyN\|gyRC:jPh?=
PANC-1	M{DEO2Z2dmO2aX;uJGF{e2G7	M3\6T\|IxKM7:TR?=	NWDRTIFkPDhiaB?=		MXnpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjFOmFZFKGmwIILld5BwdnOnIITvJJRp\SCSUFHS{tTDqGGpb37pd5TDqA>?	NXrlSnhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVQyOzNpPkK0Nlk1OTN\|PD;hQi=>
A549	Ml\CSpVv[3Srb36gRZN{[Xl?	MkfUN\|Ah\|ryP	MnXLNE42KGh?	MVLEUXNQ	MWXpcohq[mm2czD0bIUhfGi{b33ibY4ucW6mdXPl[EBKVC16L1PYR2w5NUy3YzDhZ5Rqfmm2eR?=	M3rzV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mke3Olk3Lz5{NEK3O\|Y6PjxxYU6=
SW480	MVHGeY5kfGmxbjDBd5NigQ>?	MWGxNEDPxE1?	MnnCNlAhcA>?	NYq0fJRWTE2VTx?=	M1zEWZN2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=>	Ml2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MkSzOlYoRjJ2M{K0N\|Y3RC:jPh?=
HEK 293	M4m2cmZ2dmO2aX;uJGF{e2G7	MkXvNVAh\|ryP	Mn;hOUBp	NF3RfW5FVVOR	MmnDbY5pcWKrdIOgW451NWmwZIXj[YQh\|rJvY3H0[Y5qdi:WQ1[0JIFkfGm4aYT5JIFv\CCwdXPs[YFzKM7{LXPheIVvcW5iYXPjeY12dGG2aX;u	M1fP[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0N\|Y3Lz5{NEOyOFM3PjxxYU6=
HEK 293	MnWySpVv[3Srb36gRZN{[Xl?	NYfweFFoOTBizszN	NFnwTI82KGh?	M4e2fmROW09?	NFfNelh{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk>	MljVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MkSzOlYoRjJ2M{K0N\|Y3RC:jPh?=
HL-60	MWfGeY5kfGmxbjDBd5NigQ>?	NULtcGRSOTBxMkCg{txO	MkfJNUBp		NVLaWFQzcW6qaXLpeJMhfGinwrDOMkBkcGmwZX7zbZNmgHS{YXP0xsBqdmS3Y3XkJIRq\m[ncnXueIlifGmxbjDpcpRwKGe{YX71cI9kgXSncx?=	MonqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NUewNlAoRjJ2M{W3NFIxRC:jPh?=
HL-60	MnfQSpVv[3Srb36gRZN{[Xl?	MUWyJOK2VQ>?	NXjLUVJ[OTZiaB?=	NGfGNJhFVVOR	Mlf4bY5pcWKrdIOgeIhmKGG\|c3;jbYF1cW:wIH;mJJBUPjJzIGLh[k0yKGGwZDDOSmFV[zNuIHHu[EB1cGViUlGtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gcpVkdGWjcjDOSmFV[zN?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN\|MEC2PEc,OjR\|M{CwOlg9N2F-
HeLa	NU\DVHlRTnWwY4Tpc44hSXO\|YYm=	NVjxSY1KPTBizszN	MV:wMlUhcA>?		MojDZoxw[2u\|IGTSXE0yKG63Y3zlZZIhdWmpcnH0bY9vKGGwZDDUXG5KWCCmb4fuMZJm\3WuYYTpc44>	M13SfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{e2PFI4Lz5{NEO3OlgzPzxxYU6=
HUVECs	MY\GeY5kfGmxbjDBd5NigQ>?	MWOxNOKh\|ryP	NYDkNFZbOSCq		NYHBNZZpcW6qaXLpeJMhfGinIFjEUEBz\WS3Y3XkJGNQYC1{IHX4dJJme3Orb36gZY5lKFCJST2yJJJmdGWjc3W=	NWG1OlFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFUyODlpPkK0N\|g2OTB7PD;hQi=>
MCF-7	MmfKSpVv[3Srb36gRZN{[Xl?	NFX5b5QyOMLizszN	NHzBWmUyOC9\|MDDtbY4>		Mn\odoVlfWOnczD0bIUhXVSSLXTldIVv\GWwdDDFVmsheGixc4Doc5J6dGG2aX;u	MoXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|OUC4NVkoRjJ2M{mwPFE6RC:jPh?=
HGC-27	MX3BdI9xfG:\|aYOgRZN{[Xl?	Ml:xNUDDvU1?	MVOxJIg>		M1;JUpN2eHC{ZYPz[ZMhWkGGMECxJJBtfXNiTVutNlIxPi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N?	M1joXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG2N\|Q6Lz5{NESxOlM1QTxxYU6=
PC3	NGHad\|JCeG:ydH;zbZMhSXO\|YYm=	NFK4eYQ2OCEQvF2=	NETofmQxNjViaB?=		MUHpcohq[mm2czDNTHkuPDR7LXnu[JVk\WRiYYDvdJRwe2m\|wrC=	Ml7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkS4PFkoRjJ2NEK0PFg6RC:jPh?=
HPAEpiCs	M1rPUWZ2dmO2aX;uJGF{e2G7	NHe1b2E{OCEQvF2=	Ml3RNUBp		MorlbY5pcWKrdIOgWG5HNc7zIIP0bY12dGG2ZXSgdFQzN3B2NDDNRXBMKHCqb4PwbI9zgWyjdHnvci=>	NFrnZXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0NVg4OCd-MkS0OFE5PzB:L3G+
BeWo	NGPaZVhHfW6ldHnvckBCe3OjeR?=	NH\nc2QyOMLizszN	NYLxZ2w{OiCq		NXG3OmJ4cW6qaXLpeJMhTVKNMT:y	NHvs[Jk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzN\|g1Pid-MkS0N\|M5PDZ:L3G+
A498	MmW1RZBweHSxc3nzJGF{e2G7	NUfzS4NTPTEEoN88US=>	MmjXNlQhcA>?		NYH6Sm9[eG:2ZX70bYF1\XQEoITo[UBxem9vYYDvdJRwfGmlIHXm[oVkfHNib3[gUmM>	NF\sRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwPFQ4Pid-MkS1NFg1PzZ:L3G+
NHBE	MYrGeY5kfGmxbjDBd5NigQ>?	NFfLRWUzNzJyIN88US=>	M2LHT\|IhcA>?		MX3heJRmdnWjdHXzJGlNNTN\|IIP0bY12dGG2ZXSgR3hEVDhxSVytPEB{\WO{ZYTpc44>	M3ficVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OVI3Lz5{NES3PVUzPjxxYU6=
A375	MWTD[YxtKEmwdnHzbY9vKEG\|c3H5	NFfme3oyOOLCk{KwJOK2VQ>?	MX2yOEBp		NHK1VYJz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25?	NFLlPIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2OlA{Pid-MkS0OlYxOzZ:L3G+
HBMEC	M33JS2Z2dmO2aX;uJGF{e2G7	NIO1RnEyOCEQvF2=	MnvxNUBp		NWPvUlNG[myxY3vzJHZGT0ZvaX7keYNm\CCHcHjBNkBmgHC{ZYPzbY9v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3OEm4Nkc,OjR2NUi5PFI9N2F-
HCT-15	M4X4XWZ2dmO2aX;uJGF{e2G7		MXGxJIg>		MVjheJRmdnWjdHXzJHBITTJvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrxsA>	MlXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{G0NlUoRjJ3NEOxOFI2RC:jPh?=
HCT-15	M2TSRWFxd3C2b4Ppd{BCe3OjeR?=		M2HZNVEhcA>?		MYPhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{	M4nKNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxOFI2Lz5{NUSzNVQzPTxxYU6=
786-O	Mn3tRZBweHSxc3nzJGF{e2G7	NIGzOWI2OMLizszN	MXOyOEBp		MlzydI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyOES3Okc,OjR3MEi0O\|Y9N2F-
HepG2	NX;5XnpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\ySmwzOCEQvF2=	MXiyOEBp		MXPzeZBxemW\|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v	NHrvS\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2NFQ5QCd-MkW1OlA1QDh:L3G+
SW480	NYPwVItDTnWwY4Tpc44hSXO\|YYm=	MoWzNlDDqM7:TR?=	NGXkW20yyqCq		NY[5TFM2emWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBCXEZ\|IIDyc5RmcW5?	NWW2e5JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFc5OTZpPkK1OFQ4QDF4PD;hQi=>
MDA-MB-231	M2n3cWZ2dmO2aX;uJGF{e2G7	NIjHRXYzPSEQvF2=	MonFNk0{KGh?		M4G3R4Rm[3KnYYPld{BxNUWUS{GvNkBidmRiU{GwNGE1KGW6cILld5Nqd25?	NW\u[ItKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVU5PzVpPkK1OVU2QDd3PD;hQi=>
HepG2	MmXuSpVv[3Srb36gRZN{[Xl?	MlHWNVAh\|ryP	NYjyZYlbPSCq		NVnGR5BM[myxY3vzJJBpd3OyaH;yfYxifGWmIF3BVGt{KGmwZIXj[YQh[nliZYjv[4Vvd3W\|IGTHSk3PujF?	NX3Dd4FXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlA1QDhpPkK1OVYxPDh6PD;hQi=>
MCF-7	M2Hu[mZ2dmO2aX;uJGF{e2G7	MkXsNVAh\|ryP	MmnUNUBp		NHr2Z3hqdmirYnn0d{BKVC1zOD3lcohidmOnZDDj[YxtKG2rZ4LheIlwdg>?	Ml7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkewNVEoRjJ3N{K3NFEyRC:jPh?=
H1355	NIrU[phHfW6ldHnvckBCe3OjeR?=	MoCwNlUh\|ryP	NUnmdYpCOSCq		M3zrZoJtfW62czD0bIUhSlujXWCtbY5lfWOnZDDpcoNz\WG\|ZTDpckBxcG:\|cHjvMWNpczFiYX7kJJBpd3OyaH:tSXJMKGW6cILld5Nqd25?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUG4NUc,OjV5NkmxPFE9N2F-
PC12	NXnOd3V5TnWwY4Tpc44h[XO\|YYm=				MYfJcohq[mm2aX;uJI9nKG6nco\lJIdzd3e2aDDmZYN1d3JvbXXkbYF1\WRiTVHQJItqdmG\|ZTDhZ5Rqfmm2eTDpckBpfW2jbjDQR\|EzKGOnbHzzMEBKSzVyIE2gNkDPxE1w	NFKySYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O\|M3Oyd-MUiwO\|c{PjN:L3G+
HT-29	NX64TIRiSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NF\aT3c2KGSjeYO=		M2Cye2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGfTWFEh[XO\|YYmsJGlEPTBiPTC0JO69VS5?	NHPsfpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3PFMyPid-MkWwO\|g{OTZ:L3G+
IEC6	M{DlUGZ2dmO2aX;uJIF{e2G7		NXzu[mNpPSCvaX7z		MX7Jcohq[mm2aX;uJI9nKE2HS{GvNkBqdiC{YYSgTWVEPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSXJMOS9{IHzvc5AheGixc4Doc5J6dGG2aX;uJIRwe2WmIEOwJI1qdnNiYnXmc5JmKHSxIIP0bY12dGG2aX;uJJdqfGhiMUClJJNmenWvIH\vdkA2KG2rboOgZpkhcW2vdX7vZoxwfHSrbnegcYV1cG:mLDDJR\|UxKD1iND6yJO69VS5?	NH7QR3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3PFMyPid-MkWwO\|g{OTZ:L3G+
NG 108-15	M2P0XWZ2dmO2aX;uJIF{e2G7				Mlj0R49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDhZo9tcXOqIF3BVGsh[WO2aY\peJkhcW5ibX;1d4UhdmW3cn;icIF{fG:vYTDhcoQhemG2IHfsbY9u[SCqeXLybYQhVkdiMUC4MVE2KGOnbHzzMEBC[3Srdnn0fUA:KDFyIN88UU4>	NX34dol1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1N\|c{PTRpPkG1OVM4OzV2PD;hQi=>
PC12	NWnBcJdoTnWwY4Tpc44h[XO\|YYm=	M1:xWlExKHWP	NXTLVmpjPSCqcoO=		Ml3SRYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCMTlugbY5pcWKrdH;yJHNRPjByMUK1JIZweiBzIHjyJIJm\m:{ZTDjc41xd3WwZDDh[IRqfGmxbjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MmDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|NEW2PFUoRjJzM{S1Olg2RC:jPh?=
PC12	MkC1SpVv[3Srb36gZZN{[Xl?	NIrZVJkyOCC3TR?=	MnXJOUBpenN?		MkS4RYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCPRVuyJIlvcGmkaYTvdkBWODF{NjDmc5IhOSCqcjDi[YZwemViY3;tdI92dmRiYXTkbZRqd25iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NFzs[FE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
PC12	NH21UolHfW6ldHnvckBie3OjeR?=	M1yweVExKHWP	MWW1JIhzew>?		MkPERYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCPRVuxJIlvcGmkaYTvdkBRTDl6MEW5JIZweiBzIHjyJIJm\m:{ZTDjc41xd3WwZDDh[IRqfGmxbjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NEX1TIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
HeLa	M4PMSGZ2dmO2aX;uJIF{e2G7	M4T4SVIxKHWP	NV3ZR2pvOyCqcoO=		MVjJcohq[mm2aX;uJI9nKEWUS{GvNkBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCB{MDD1UUBi\nSncjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	MmmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{C2NVUoRjJ\|NUewOlE2RC:jPh?=
RD	MnfQdWhVWyCjc4PhfS=>				MlXwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MoHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MWPxTHRUKGG\|c3H5				NV3QVXlqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NFLBepA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	M2rTXpFJXFNiYYPzZZk>				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?=	NX3E[2FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M2Xhd5FJXFNiYYPzZZk>				NELqSHRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NWLFPWpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	M4LDc5FJXFNiYYPzZZk>				MoD0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	NF\x[VM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MDA-MB-231	M2\WZ2Z2dmO2aX;uJIF{e2G7	MorROVAhfU1?			MV;Ec5dvemWpdXzheIlwdiCxZjDNUXAzKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiNUCgeW0h[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M2XTOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK2NlI3Lz5{MkmyOlIzPjxxYU6=
MDA-MB-231	M3eyWWZ2dmO2aX;uJIF{e2G7	MlvYOVAhfU1?			Mm\DSI94dnKnZ4XsZZRqd25ib3[gUW1RQSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEWwJJVOKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NIHVNmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyOlIzPid-MkK5NlYzOjZ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; PubMed: 17482134 Cancer cell ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-JNK / JNK / Cyclin D1 ; PubMed: 17482134 Cancer cell Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-HER2 / HER2 ; PubMed: 24244023 J Immunol TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. MMP9 / XIAP / VEGF ; PubMed: 29695559 In Vivo SK-Hep1 cells were treated 10 μM PD98059 for 48 h. Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.	17482134 24244023 29695559

体内研究

在大脑缺血前30分钟用PD98059处理小鼠可以明显减轻伤害, 使脑梗塞的体积减小^[4]。基于胰腺的湿重和组织学研究发现，提前30分钟用PD98059预处理 (10 mg/kg 静脉注射) 然后每小时注射一次蛙皮素连续三次的小鼠可以明显改善蛙皮素诱导的急性胰腺炎^[7]。卡拉胶损伤一小时后用PD98059 (10 mg/kg) 对小鼠进行治疗可以发现与炎症相关的所有指标均有所下降^[11]。

激酶实验： ^[1]	- 合并体外MEK激酶活性测定: 在含有44-kDa GST-MAPK 或者45-kDa GST-MEK1的体系中检测³²P被掺入蛋白 MBP中的情况。反应体系50 μL ，含有50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP，加入10 μg GST-MEK1, 0.5 μg GST-MAPK和 40 μg MBP。30°C 孵育15 分钟, 加入Laemmli SDS 样品缓冲液终止反应。磷酸化的MBP 进行10% SDS-PAGE分析
细胞实验： ^[1]	- 合并 Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, 和K562 Concentrations: 溶于DMSO, 终浓度~100 μM Incubation Time: 3 天, 或者7-10天 Method: 细胞按10,000-20,000个/mL的密度接种在多孔平板中进行单层生长。48小时后把不同浓度的PD98059 加到细胞培养基孵育3天。然后通过胰酶将细胞从平板中消化下来并用Coulter 计数器计数。将细胞按5,000-10,000每皿的浓度接种在35 mm的培养皿中，培养基中含有0.3% 的琼脂和期望浓度的PD98059，让细胞在软琼脂上生长.经过7-10天的生长, 可以借助解剖显微镜将可见的菌落数出来。 (Only for Reference)
动物实验： ^[7]	- 合并 Animal Models: 患有急性胰腺炎的雄性Sprague–Dawley 大鼠 Dosages: 10 mg/kg Administration: 静脉注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	1mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PD98059 SDF

分子量	267.28
化学式	C₁₆H₁₃NO₃
CAS号	167869-21-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to formulate this inhibitor for i.p. injection?
回答：
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

泛MEK抑制剂

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM.
活性最高的MEK抑制剂

PD0325901 : MEK, IC50=0.33 nM.
FDA批准的MEK抑制剂

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
最新的MEK抑制剂

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

研究领域

产品类型

定制您的化合物库

PD98059

客户使用Selleck生产的PD98059发表文献353篇：

产品安全说明书

MEK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PD98059 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

相关MEK产品